Mycoplasma Testing Market Size, Share, Growth Analysis, By Product & Service(Assays, Kits, & Reagents (NAT Assays, Kits), By Technique(Nucleic Acid Testing, Enzyme-Linked Immunosorbent Assay, Staining, Other Techniques), By Application(Cell Line Testing, Virus Testing, End-Of-Production Cell Testing), By End User(Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutes, Cell Banks & Laboratories), By Region - Industry Forecast 2025-2032

Mycoplasma Testing Market size was valued at USD 9110.23 Million in 2023 and is poised to grow from USD 9995.74 Million in 2024 to USD 2097.61 Million by 2032, growing at a CAGR of 9.72% during the forecast period (2025-2032).

Growth and innovations in the diagnostic sector have created an opportunity for mycoplasma testing market size because of the rising contaminations of mycoplasma within the pharmaceutical and biotechnology industry producing mycoplasma testing products. Main mycoplasma testing market growth drivers include rising research initiatives in the biotechnology and the biopharmaceutical industries, and the higher demand of the mycoplasma testing kits by the biopharmaceutical industry. The mycoplasma testing market share will increase due to emerging markets because of the better infrastructure for healthcare, an increased unmet healthcare demands, and the rising incidence of mycoplasma contamination. As a matter of fact, rules and regulations mandating testing for biologics and vaccines for mycoplasma contamination have been published by regulatory bodies, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Due to this, a heightened demand for mycoplasma testing has been witnessed in the biopharmaceutical sector. Also, technical innovations are inclined to lead to the mycoplasma testing market share, including faster and more accurate procedures and equipment for mycoplasma testing. The latest instance is Minerva Biolabs GmbH's VenorGeM Advance assay, highly sensitive and specific, which targets mycoplasma contamination in biological matrices of cell cultures.

US Mycoplasma Testing Market is poised to grow at a sustainable CAGR for the next forecast year.